Prestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Jennison Associates LLC

Jennison Associates LLC decreased its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 3.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 410,937 shares of the company’s stock after selling 15,378 shares during the quarter. Jennison Associates LLC’s holdings in Prestige Consumer Healthcare were worth $29,629,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Opal Wealth Advisors LLC purchased a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at approximately $26,000. Quest Partners LLC grew its position in shares of Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after acquiring an additional 424 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Prestige Consumer Healthcare by 80.6% in the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock valued at $33,000 after buying an additional 208 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in Prestige Consumer Healthcare by 562.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after acquiring an additional 433 shares during the period. Finally, Gladius Capital Management LP acquired a new stake in shares of Prestige Consumer Healthcare during the second quarter worth $35,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on PBH shares. DA Davidson reissued a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Jefferies Financial Group reissued a “hold” rating and set a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Insider Buying and Selling

In other news, EVP Adel Mekhail sold 9,063 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total value of $743,166.00. Following the transaction, the executive vice president now owns 18,365 shares of the company’s stock, valued at $1,505,930. The trade was a 33.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock worth $3,187,300 in the last three months. 1.60% of the stock is owned by insiders.

Prestige Consumer Healthcare Price Performance

PBH opened at $84.09 on Friday. Prestige Consumer Healthcare Inc. has a twelve month low of $56.61 and a twelve month high of $84.28. The firm has a market cap of $4.15 billion, a price-to-earnings ratio of 20.46, a PEG ratio of 2.32 and a beta of 0.47. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The company has a fifty day simple moving average of $73.91 and a 200 day simple moving average of $70.48.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting analysts’ consensus estimates of $1.09. The firm had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm’s revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.07 EPS. Equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.